December 31, 2024
TOPLINE: Compared with cetuximab with concurrent radiotherapy, adjuvant durvalumab alongside radiotherapy did not enhance outcomes in patients with head and neck squamous cell carcinoma (HNSCC) who […]
December 30, 2024
TOPLINE: Aggressive margin reduction with MRI-guided stereotactic body radiotherapy (SBRT) led to a significantly lower incidence of late genitourinary and gastrointestinal toxicities at 2 years compared […]
December 24, 2024
TOPLINE: Implementing a home-based exercise program alongside management strategies did not improve patients’ self-reported physical function after lung cancer surgery but did enhance exercise capacity, health-related […]
December 24, 2024
LONDON (Reuters) -AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU’s medicines regulator for its experimental precision drug for the treatment of a type […]
December 23, 2024
The cutting edge of treating solid tumors with cell therapies got notably sharper this year. First came the US Food and Drug Administration (FDA) approval in […]
December 23, 2024
TOPLINE: Age-standardized mortality rates for hepatocellular carcinoma (HCC) in the United States are expected to rise from 5.03 per 100,000 persons in 2022 to 6.39 per […]
December 23, 2024
TOPLINE: Short-course vaginal cuff brachytherapy (VCB) demonstrated noninferiority in quality of life for patients with early endometrial cancer vs standard regimens, in a prospective randomized trial. […]
December 23, 2024
SAN DIEGO — Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer product to become the […]
December 23, 2024
Do patients with early-stage non–small cell lung cancer (NSCLC) benefit from continuing immunotherapy beyond surgery? The short answer: Oncologists don’t know for sure. Since October 2023, […]